<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01788930</url>
  </required_header>
  <id_info>
    <org_study_id>1227</org_study_id>
    <nct_id>NCT01788930</nct_id>
  </id_info>
  <brief_title>Aspirin Resistance and Sleep Apnea in Type-2 Diabetic Patients</brief_title>
  <acronym>AREAS</acronym>
  <official_title>Obstructive Sleep Apnea and Aspirin Resistance in Type-2 Diabetic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Type-2 Diabetes and Sleep Apnea Syndrome (SAS) are both related to an increase in platelet
      activation. Type 2 diabetes is often associated with sleep apnea syndrome with a prevalence
      up to 60%.

      The main objective of our study is to analyze the influence of sleep apnea on the response to
      antiplatelet therapy in stable aspirin-treated type-2 diabetes patients.

      Consecutive stable aspirin-treated type-2 diabetes patients referred for suspicion of sleep
      apnea will be recruited after providing informed consent. Response to aspirin will be
      assessed with the Verify Now Aspirin(TM)rapid analyser in the morning after nocturnal
      polysomnography, and compared with a group of type-2 diabetes free of sleep apnea. Other
      endocrine, metabolic, hematologic and cardiovascular confounders will also be assessed at
      baseline to determine their influence on the response to aspirin.

      Then, Patients with severe SAS (Apnea-Hypopnea Index&gt; 30 events/h) and response with Aspirin
      (ARU &gt; 454) will be randomized to 3 months of active or sham continuous positive airway
      pressure treatment in a pilot study. After the 3-months of intervention, response to aspirin
      will be compared between the sham and effective CPAP groups.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">October 2017</completion_date>
  <primary_completion_date type="Actual">July 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response to antiplatelet therapy</measure>
    <time_frame>Measure will be done in the morning after the sleep diagnosis</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effects of CPAP treatment for severe obstructive sleep apnea on aspirin efficacity in type-2 diabetic patients</measure>
    <time_frame>Change from baseline after 3 months randomized treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">286</enrollment>
  <condition>Atherothrombosis</condition>
  <condition>Type 2 Diabetes</condition>
  <condition>Obstructive Sleep Apnea Syndrome</condition>
  <arm_group>
    <arm_group_label>CPAP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This device consists in a nasal continuous positive airway pressure (CPAP). It will be applied 3 months after the beginning of drug treatment and for 3 months.
Other Name: positive airway pressure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham-CPAP</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>This device consists in a sham CPAP. It will be applied 3 months after the beginning of drug treatment and for 3 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CPAP</intervention_name>
    <arm_group_label>CPAP</arm_group_label>
    <arm_group_label>Sham-CPAP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women aged &gt; 18 years old

          -  With Type 2 diabetes

          -  Stable Atherothrombosis for more than 3 months

          -  Using aspirin for more than 10 days or without aspirin (in this last case, they will
             do only the observational study.)

          -  Without any modification in their treatments for 10 days

          -  Ambulatory patient

          -  Without any cardiovascular event or inflammatory disease for 3 months before inclusion

        Exclusion Criteria:

          -  Pregnant women

          -  Other active clinically significant illness, including unstable cardiovascular, or
             neoplasia which could interfere with the study conduct or counterindicate the study
             treatments or place the patient at risk during the trial or compromise the study
             participation

          -  Patients participating in an other study

          -  Patient without any medical care insurance

          -  Any treatment that could interfere with aspirin

          -  Previous treatment by CPAP
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olivier ORMEZZANO, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Grenoble</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Olivier ORMEZZANO, MD, PhD</last_name>
    <phone>+33 4 76 76 75 75</phone>
    <email>OOrmezzano@chu-grenoble.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jean-Louis PEPIN, MD, PhD</last_name>
    <phone>+ 33 4 76 76 55 16</phone>
    <email>JPepin@chu-grenoble.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Grenoble University Hospital</name>
      <address>
        <city>Grenoble</city>
        <state>Isere</state>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie PEETERS</last_name>
      <phone>+334 76 76 92 65</phone>
      <email>MPeeters@chu-grenoble.fr</email>
    </contact>
    <investigator>
      <last_name>Olivier ORMEZZANO, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Louis PEPIN, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Patrick LEVY, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Renaud TAMISIER, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sandrine LAUNOIS, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre-Yves BENHAMOU, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne-Laure BOREL, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nelly WION-BARBOT, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Patrice FAURE, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Françoise STANKE, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Philippe BAGUET, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gérald VANZETTO, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Patrick CARPENTIER, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christophe SEINTURIER, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jacqueline YVER, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gilles PERNOD, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Benoit POLACK, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Raphael MARLU, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cécile BOSC, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie DESTORS, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 7, 2013</study_first_submitted>
  <study_first_submitted_qc>February 7, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2013</study_first_posted>
  <last_update_submitted>September 27, 2017</last_update_submitted>
  <last_update_submitted_qc>September 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

